case_images: PMC4025148_01
case_images: Response characteristics from combination TTFields and bevacizumab therapy. At the time of first recurrence, the tumor cyst measured 3.4 x 4.4 cm on gadolinium-enhanced T1-weighted (a) and FLAIR (b) images. After 2 cycles of bevacizumab, there was a partial decrease in the size of the cystic tumor to 1.9 x 3.6 cm as seen on gadolinium-enhanced T1-weighted images (c) and a partial resolution of the edema as detected on FLAIR (d) images. After 6 cycles of combination TTFields and bevacizumab therapy, there was a further decrease of the cystic tumor to 1.7 x 3.1 cm, or 65% reduction, as seen on gadolinium-enhanced T1-weighted images (e) and a resolution of edema as detected on FLAIR (f) images.
case_images: crn-0006-0109-g01.jpg
case_images: PMC4025148_01_crn-0006-0109-g01.jpg
case_images: F1
case_images: After 5 cycles of adjuvant temozolomide, new cystic enhancement was discovered while performing a head MRI (fig. 1a, b), and she was placed on 4 mg of dexamethasone 4 times/day. After 2 cycles of bevacizumab, there was only a partial decrease in the gadolinium enhancement and the size of the cystic tumor (fig. 1c, d). After a total of 6 cycles of bevacizumab plus TTFields therapy, with a respective mean and median compliance of 17.6 hours (73% of the day) and 18.4 hours (77% of the day) (range 3.6 to 22.8 h), there was a near complete resolution of gadolinium enhancement and a 65% reduction in the size of the cystic tumor (fig. 1e, f).
case_images: Foci of relapsed disease outside of the previously irradiated glioblastoma. Gadolinium enhancement was detected in the internal capsule (a) and medial left frontal brain (b) after 6 cycles of TTFields and bevacizumab therapy.
case_images: crn-0006-0109-g02.jpg
case_images: PMC4025148_01_crn-0006-0109-g02.jpg
case_images: F2
case_images: However, there were also recurrent tumors detected in the left internal capsule and the medial left frontal brain (fig. 2a, b), which were located outside of the prior radiation treatment fields.